Content by Bio-Rad Laboratories

Under the new partnership, Biodesix will lead development and regulatory efforts for Bio-Rad’s ddPLEX ESR1 assay, enabling sensitive ctDNA-based mutation testing.

Bio-Rad Laboratories, Inc has launched four new Droplet Digital PCR platforms.

Bio-Rad has expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies and SpyCatcher reagents, enhancing support for bioanalytical assay development and antibody drug research.

Monitoring ctDNA enables earlier detection, real-time assessment of treatment response, and more personalized strategies that improve patient outcomes across a range of tumor types.

Learn how stain-free technology eliminates the hassles of traditional western blot staining and enhances reproducibility.

Advances in flow cytometry are accelerating drug discovery by enabling high-throughput, automated single-cell analysis.

Understanding assay sensitivity and precision is essential for generating reliable, reproducible PCR data in research and clinical settings.

 Learn how researchers can transition RNA therapeutics from bench to clinic using Droplet Digital PCR solutions.

Researchers can achieve seamless western blot experiments by implementing advancements in stain-free technology, normalization methods, and compliance integration. 

Advanced gene editing, delivery, and analytical tools are driving better gene therapies.